Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Envista Holdings Corporation (NVST)

NYSE: NVST · Dental Equipment & Supplies · Brea, CA

Our rating: Cautious

Cautious reaffirmed at $24.03, moderate conviction, November 16, 2026.

Breaks if: The Cautious call is wrong if Envista's next two quarterly filings — covering the six months through mid-2027 — together show cumulative free cash flow above $110M and year-over-year revenue growth at or above 7% in each period, confirming that the November patent invalidations have not impaired cash generation or top-line momentum. If both conditions hold simultaneously, the IP damage looks contained and the basis for Cautious dissolves.

Key figures

Market value$3.7B
Revenue, last 12 months$2.9B
Net income, last 12 months$634M
Free cash flow, last 12 months$242M
Price to earnings5.8×
Free cash flow yield6.6%
Dividend yield0.0%
Operating margin25.4%
Return on equity20.5%
Beta to the S&P 5001.18
Volatility, annualized40.2%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
October 2, 2026$692M3.2%$3.11$62M
July 3, 2026$731M7.1%$0.33$104M
April 3, 2026$706M14.4%$0.23−$16M
December 31, 2025$751M15.0%$0.20$92M
September 26, 2025$670M11.5%$-0.18$68M
June 27, 2025$682M7.7%$0.16$76M
March 28, 2025$617M−1.1%$0.10−$6M
December 31, 2024$653M1.1%$0.01$124M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 31 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.